Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04032626 · ClinicalTrials.gov registry record · Phase 2
MCLENA-1: A Clinical Trial for the Assessment of Lenalidomide in Amnestic MCI Patients
A Phase 2 study, sponsored by St. Joseph's Hospital and Medical Center, Phoenix.
- Completed
- Registry status
- Phase 2
- Development phase
- 15
- Enrollment target
NCT04032626 is a Phase 2 study that has completed, run by St. Joseph's Hospital and Medical Center, Phoenix. The registered enrollment target is 15 participants.
The verdict
NCT04032626, a Phase 2 study, has completed, sponsored by St. Joseph's Hospital and Medical Center, Phoenix.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 15 participants
- Enrollment target
Study Summary
Accumulating evidence indicates that inflammation is prominent both in the blood and central nervous system (CNS) of Alzheimer's disease (AD) patients. These data suggest that systemic inflammation plays a crucial role in the cause and effects of AD neuropathology. Capitalizing on the experience from a previous clinical trial with thalidomide, here, the investigators hypothesize that modulating both systemic and CNS inflammation via the pleiotropic immunomodulator lenalidomide is a putative therapeutic intervention for AD if administered at a proper time window during the course of the disease.
Interventions
- DRUG Placebo
- DRUG Lenalidomide 10 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2020-07-22 |
| Est. Completion | 2025-05-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04032626
The ClinicalTrials.gov registry entry for NCT04032626 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is St. Joseph's Hospital and Medical Center, Phoenix, which has 44 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04032626 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04032626 about?
NCT04032626 is a clinical study titled "MCLENA-1: A Clinical Trial for the Assessment of Lenalidomide in Amnestic MCI Patients". Accumulating evidence indicates that inflammation is prominent both in the blood and central nervous system (CNS) of Alzheimer's disease (AD) patients. These data suggest that systemic inflammation plays a crucial role in the cause and effects of AD neuropathology. Capitalizing on the experience fro...
What is the current status of trial NCT04032626?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 15 participants. The study started on 2020-07-22. Estimated completion is 2025-05-31.
What interventions are being tested in trial NCT04032626?
The interventions under investigation include: Placebo (DRUG), Lenalidomide 10 mg (DRUG).
Who is sponsoring clinical trial NCT04032626?
This trial is sponsored by St. Joseph's Hospital and Medical Center, Phoenix, which has 44 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.